{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:21:44Z","timestamp":1762867304410},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.bulcan.2017.10.022","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T06:00:37Z","timestamp":1511330437000},"page":"S181-S187","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S","title":["Conduite \u00e0 tenir devant une r\u00e9activation EBV et un syndrome lymphoprolif\u00e9ratif \u00e0 EBV, une r\u00e9activation ou infection \u00e0 CMV et \u00e0 HHV-6\u00a0apr\u00e8s allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques\u00a0: recommandations de la SFGM-TC (mises \u00e0 jour)"],"prefix":"10.1016","volume":"104","author":[{"given":"Eolia","family":"Brissot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamim","family":"Alsuliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9reng\u00e8re","family":"Gruson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hermet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yordanka","family":"Tirefort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Alain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11S","key":"10.1016\/j.bulcan.2017.10.022_bib0115","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"[How we harmonize HSCT clinical practices among the SFGM-TC centers]","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2017.10.022_bib0120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.patbio.2013.07.003","article-title":"[Diagnosis and treatment of CMV and EBV reactivation as well as post-transplant lymphoproliferative disorders following allogeneic stem cell transplantation: an SFGM-TC report]","volume":"61","author":"Bay","year":"2013","journal-title":"Pathol Biol (Paris)"},{"issue":"7","key":"10.1016\/j.bulcan.2017.10.022_bib0125","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1128\/JCM.03336-15","article-title":"Multicenter evaluation of whole-blood Epstein-Barr viral load standardization using the WHO international standard","volume":"54","author":"Semenova","year":"2016","journal-title":"J Clin Microbiol"},{"issue":"19","key":"10.1016\/j.bulcan.2017.10.022_bib0130","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bulcan.2017.10.022_bib0135","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2015.64.2405","volume":"34","author":"Styczynski","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2017.10.022_bib0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bmt.2011.28","article-title":"In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT","volume":"47","author":"Dominietto","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2017.10.022_bib0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.bulcan.2017.10.022_bib0150","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.bulcan.2017.10.022_bib0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"Management of cytomegalovirus infection in haemopoietic stem cell transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.bulcan.2017.10.022_bib0160","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1093\/cid\/cir002","article-title":"Influence of donor cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell transplantation in CMV-seropositive recipients","volume":"52","author":"Pietersma","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.bulcan.2017.10.022_bib0165","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/j.1537-2995.2011.03203.x","article-title":"Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME)","volume":"51","author":"Thiele","year":"2011","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.bulcan.2017.10.022_bib0170","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00002030-200003310-00007","article-title":"Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients","volume":"14","author":"Anduze-Faris","year":"2000","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.bulcan.2017.10.022_bib0175","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2011.12.579","article-title":"Early human herpesvirus type\u00a06\u00a0reactivation after allogeneic stem cell transplantation: a large-scale clinical study","volume":"18","author":"Dulery","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2017.10.022_bib0180","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/CMR.18.1.217-245.2005","article-title":"Update on human herpesvirus\u00a06\u00a0biology, clinical features, and therapy","volume":"18","author":"De Bolle","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.bulcan.2017.10.022_bib0185","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jcv.2008.08.008","article-title":"Human herpesvirus type\u00a06\u00a0reactivation after haematopoietic stem cell transplantation","volume":"43","author":"de Pagter","year":"2008","journal-title":"J Clin Virol"},{"issue":"1","key":"10.1016\/j.bulcan.2017.10.022_bib0190","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bbmt.2006.09.003","article-title":"Risk factors for developing human herpesvirus\u00a06 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders","volume":"13","author":"Yamane","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2017.10.022_bib0195","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/QCO.0b013e3283553362","article-title":"Human herpesvirus\u00a06 (HHV-6) disease in the setting of transplantation","volume":"25","author":"Zerr","year":"2012","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"10.1016\/j.bulcan.2017.10.022_bib0200","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jcv.2011.06.008","article-title":"Deciphering the clinical impact of acute human herpesvirus\u00a06 (HHV-6) infections","volume":"52","author":"Agut","year":"2011","journal-title":"J Clin Virol"},{"issue":"11","key":"10.1016\/j.bulcan.2017.10.022_bib0205","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.bbmt.2010.05.009","article-title":"High incidence of human herpes virus 6-associated encephalitis\/myelitis following a second unrelated cord blood transplantation","volume":"16","author":"Mori","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2017.10.022_bib0210","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cid\/cit358","article-title":"Human herpesvirus\u00a06 (HHV-6) reactivation and HHV-6\u00a0encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study","volume":"57","author":"Ogata","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.bulcan.2017.10.022_bib0215","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/bmt.2008.162","article-title":"Management of CMV, HHV-6, HHV-7\u00a0and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT","volume":"42","author":"Ljungman","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2017.10.022_bib0220","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/rmv.715","article-title":"Chromosomally integrated human herpesvirus\u00a06: questions and answers","volume":"22","author":"Pellett","year":"2012","journal-title":"Rev Med Virol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117303077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117303077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T03:11:33Z","timestamp":1531105893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455117303077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0007455117303077"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.10.022","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conduite \u00e0 tenir devant une r\u00e9activation EBV et un syndrome lymphoprolif\u00e9ratif \u00e0 EBV, une r\u00e9activation ou infection \u00e0 CMV et \u00e0 HHV-6\u00a0apr\u00e8s allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques\u00a0: recommandations de la SFGM-TC (mises \u00e0 jour)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}